Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences
September 03 2019 - 8:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company
committed to developing medicines that transform the lives of
people with rare neurological diseases, today announced its
participation in two upcoming investor conferences in September:
- Citi’s 14th Annual Biotech ConferenceMembers
of the Company’s management team will participate in one-on-one
meetings with investors on Thursday, September 5, 2019. The
conference will be held at the Four Seasons Hotel in Boston,
MA.
- Ladenburg Thalmann’s 2019 Healthcare
Conference Jeremy Levin, DPhil, MB, BChir, Chairman and
Chief Executive Officer of Ovid, will present a corporate overview
on Tuesday, September 24, 2019 at 9:00 a.m. EDT. Ovid will
also participate in one-on-one meetings with investors. The
conference will be held at the Sofitel Hotel in New York, NY.
A live audio webcast of the presentation at the Ladenburg
conference can be accessed through the Events & Presentations
section of the company's website at investors.ovidrx.com. An
archived replay of the webcast will be available on the company's
website for two weeks following the live presentation.
About Ovid TherapeuticsOvid Therapeutics
(NASDAQ: OVID) is a New York-based biopharmaceutical company using
its BoldMedicine® approach to develop medicines that transform the
lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing OV935
(soticlestat) in collaboration with Takeda Pharmaceutical Company
Limited for the potential treatment of rare developmental and
epileptic encephalopathies (DEE).
For more information on Ovid, please visit
http://www.ovidrx.com/.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns McClellan,
Inc.sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman1ABkatie@1abmedia.com
(919) 333-7722
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Sep 2023 to Sep 2024